Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 open-label randomized study of luspatercept versus epoetin alfa for transfusion-dependent anemia in lower-risk myelodysplastic syndromes
MOH_2020-09-30_009373Phase 3Not yet recruiting
- Sponsor
- Insmed Incorporated
- Start
- Jul 2020
- Modality
- Recombinant Proteins and Enzymes, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in myelodysplastic syndrome (MDS) and anaemia comparing Luspatercept with Epoetin alfa (2 arms). Planned start Jul 2020; status: not yet recruiting.
02
Drugs
luspaterceptepoetin alfa
03
Conditions
myelodysplastic syndrome (MDS)anaemia
Beyond the preview
Go deeper on MOH_2020-09-30_009373.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2020-09-30_009373.